ORAVIG Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Oravig, and when can generic versions of Oravig launch?
Oravig is a drug marketed by Galt Pharms and is included in one NDA. There are three patents protecting this drug.
This drug has twenty-four patent family members in fourteen countries.
The generic ingredient in ORAVIG is miconazole. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the miconazole profile page.
DrugPatentWatch® Generic Entry Outlook for Oravig
Indicators of Generic Entry
Summary for ORAVIG
| International Patents: | 24 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 110 |
| Patent Applications: | 4,057 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ORAVIG |
| What excipients (inactive ingredients) are in ORAVIG? | ORAVIG excipients list |
| DailyMed Link: | ORAVIG at DailyMed |
Pharmacology for ORAVIG
| Drug Class | Azole Antifungal |
Anatomical Therapeutic Chemical (ATC) Classes for ORAVIG
US Patents and Regulatory Information for ORAVIG
ORAVIG is protected by three US patents.
Patents protecting ORAVIG
Prolonged release bioadhesive therapeutic systems
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF OROPHARYNGEAL CANDIDIASIS
Prolonged release bioadhesive therapeutic systems
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF OROPHARYNGEAL CANDIDIASIS
Prolonged release bioadhesive therapeutic systems
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galt Pharms | ORAVIG | miconazole | TABLET;BUCCAL | 022404-001 | Apr 16, 2010 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Galt Pharms | ORAVIG | miconazole | TABLET;BUCCAL | 022404-001 | Apr 16, 2010 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Galt Pharms | ORAVIG | miconazole | TABLET;BUCCAL | 022404-001 | Apr 16, 2010 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ORAVIG
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Galt Pharms | ORAVIG | miconazole | TABLET;BUCCAL | 022404-001 | Apr 16, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
| Galt Pharms | ORAVIG | miconazole | TABLET;BUCCAL | 022404-001 | Apr 16, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
| Galt Pharms | ORAVIG | miconazole | TABLET;BUCCAL | 022404-001 | Apr 16, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ORAVIG
See the table below for patents covering ORAVIG around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Cyprus | 1107828 | ⤷ Try a Trial | |
| European Patent Office | 1408911 | SYSTEMES THERAPEUTIQUES BIOADHESIFS A LIBERATION PROLONGEE (SUSTAINED-RELEASE THERAPEUTIC BIOADHESIVE SYSTEMS) | ⤷ Try a Trial |
| Spain | 2294170 | ⤷ Try a Trial | |
| France | 2827517 | SYSTEMES THERAPEUTIQUES BIOADHESIFS A LIBERATION PROLONGEE | ⤷ Try a Trial |
| Japan | 4657603 | ⤷ Try a Trial | |
| Austria | 373464 | ⤷ Try a Trial | |
| Denmark | 1408911 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
DrugChatter - AI-based answers to questions about drugs
RxJam - Trigger-based marketing for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
